Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 659 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prostate Radiation Clear all
Recruiting Phase 3 Interventional

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

NCT06855277
View directory record Official record
Conditions
Prostate Cancer
Interventions
AAA817, ARPI, Standard of Care
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
42
States / cities
Homewood, Alabama • Tucson, Arizona • Orange, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 23, 2026, 4:17 PM EDT
Recruiting Not applicable Interventional

Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy

NCT00969111
View directory record Official record
Conditions
Prostate Cancer
Interventions
IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Proton (prostate bed) to 70.2 CGE, IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Proton to 66.6 CGE
Radiation
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2050
U.S. locations
6
States / cities
Little Rock, Arkansas • Jacksonville, Florida • Warrenville, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 4:17 PM EDT
Recruiting Phase 3 Interventional

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

NCT04423211
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
3-Dimensional Conformal Radiation Therapy, Apalutamide, Computed Tomography, Degarelix, External Beam Radiation Therapy, Fluciclovine F18, Goserelin Acetate, Intensity-Modulated Proton Therapy, Intensity-Modulated Radiation Therapy, Leuprolide Acetate, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Volume Modulated Arc Therapy
Radiation · Drug · Procedure + 1 more
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
341
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 23, 2026, 4:17 PM EDT
Completed No phase listed Observational

Prospective Evaluation of a Commercially Available Hydrogel Spacer

NCT05323747
View directory record Official record
Conditions
Prostate Cancer
Interventions
Observation
Other
Lead sponsor
BioProtect
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Campbell, California • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 23, 2026, 4:17 PM EDT
Completed Phase 2 Interventional

Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)

NCT00855647
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Hypo-fractionated Radiotherapy
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 23, 2026, 4:17 PM EDT
Completed Not applicable Interventional

High Dose-Rate Brachytherapy and/or Intensity Modulated External Beam Radiation Therapy for Prostate Cancer

NCT00243321
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
high dose-rate brachytherapy, intensity-modulated radiation therapy
Procedure
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 23, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

RecoverPC: Relugolix vs GnRH Agonist in Quality of Life

NCT05765500
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
Relugolix, Leuprolide
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • Foxborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy

NCT07686380
View directory record Official record
Conditions
Recurrent Prostate Cancer, Prostate Cancer
Interventions
N-803, ETBX-71 Vaccine, 18F-DCFPyL
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 4:17 PM EDT
Active, not recruiting Phase 2 Interventional

Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer

NCT04253483
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
Interventions
High-Dose Rate Brachytherapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Ablative Radiotherapy
Radiation · Other · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Livingston, New Jersey • New Brunswick, New Jersey • Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 23, 2026, 4:17 PM EDT
Completed Phase 2 Interventional

Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer

NCT00039624
View directory record Official record
Conditions
Prostate Cancer
Interventions
Brachytherapy
Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 90 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 23, 2026, 4:17 PM EDT
Suspended Phase 1Phase 2 Interventional

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

NCT06643494
View directory record Official record
Conditions
Prostate Cancer
Interventions
N-111, Placebo
Dietary Supplement · Other
Lead sponsor
Optimal Health Research
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 23, 2026, 4:17 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer

NCT02135445
View directory record Official record
Conditions
Prostate Cancer
Interventions
TAK-385, Degarelix
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 23, 2026, 4:17 PM EDT
Completed Not applicable Interventional Results available

Genomics in Michigan Impacting Observation or Radiation

NCT02783950
View directory record Official record
Conditions
Prostate Cancer
Interventions
Decipher Prostate Cancer Classifier
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
13
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 23, 2026, 4:17 PM EDT
Withdrawn Phase 2 Interventional

Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer

NCT01087580
View directory record Official record
Conditions
PROSTATE CANCER
Interventions
Docetaxel and Prednisone, Radiation Therapy
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 23, 2026, 4:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer

NCT06574880
View directory record Official record
Conditions
Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer
Interventions
Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Angela Y. Jia, MD PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 23, 2026, 4:17 PM EDT
Recruiting Not applicable Interventional

Evaluating Tolerability of ePUHRT With Brachytherapy Boost

NCT06817668
View directory record Official record
Conditions
Prostate Cancer
Interventions
ePURT 5Gy x 5 fractions with single HDR boost of 15Gy
Radiation
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 26, 2025 · Synced Oct 23, 2026, 4:17 PM EDT
Recruiting No phase listed Observational

Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer

NCT04775355
View directory record Official record
Conditions
Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Cancer AJCC v7
Interventions
Biospecimen Collection, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 4:17 PM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

NCT00067015
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, goserelin acetate, assessment of therapy complications, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 23, 2026, 4:17 PM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy Followed by Surgery in High-Risk, Localized Carcinoma of the Prostate

NCT00691977
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy followed by prostatectomy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
Up to 69 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Oct 23, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

NCT07393867
View directory record Official record
Conditions
Intermediate Risk Prostate Cancer, High Risk Prostate Cancer, Prostate Cancer
Interventions
PSMA PET/CT, Androgen Deprivation Therapy (ADT) +/- bicalutamide, Stereotactic Body Radiation Therapy (SBRT) +/- focal microboost
Diagnostic Test · Drug · Radiation
Lead sponsor
Martin T. King, MD, PhD
Other
Eligibility
18 Years and older · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Milford, Massachusetts • Weymouth, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 23, 2026, 4:17 PM EDT
Not yet recruiting Phase 2 Interventional

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

NCT06129851
View directory record Official record
Conditions
Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Bone Scan, Brachytherapy, Computed Tomography, Dual X-ray Absorptiometry, External Beam Radiation Therapy, Magnetic Resonance Imaging, PSMA PET Scan, Questionnaire Administration, Relugolix
Procedure · Radiation · Other + 1 more
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 23, 2026, 4:17 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer

NCT00924807
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate, Bicalutamide, Sorafenib
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 23, 2026, 4:17 PM EDT
Recruiting Phase 2 Interventional

Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial

NCT06378866
View directory record Official record
Conditions
Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer, Biochemically Recurrent Prostate Carcinoma
Interventions
Abiraterone, Apalutamide, Biospecimen Collection, Bone Scan, Computed Tomography, Darolutamide, Degarelix, Enzalutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Imaging, Patient Observation, Positron Emission Tomography, Prednisone, Questionnaire Administration, Relugolix, Stereotactic Body Radiation Therapy, Triptorelin, Radiation Therapy, Image-Guided Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
532 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 23, 2026, 4:17 PM EDT
Completed Phase 1 Interventional

A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057

NCT02916537
View directory record Official record
Conditions
Prostate Cancer
Interventions
CTT1057, Prostatectomy
Drug · Procedure
Lead sponsor
Cancer Targeted Technology
Industry
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 23, 2026, 4:17 PM EDT